SEARCH

SEARCH BY CITATION

References

  • 1
    Bush K. The impact of β-lactamases on the development of novel antimicrobial agents. Curr Opin Infect Drugs 2002; 3: 12841290.
  • 2
    Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331344.
  • 3
    Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin Invest Drugs 2002; 11: 529544.
  • 4
    Iso Y, Irie T, Iwaki T et al. Synthesis and modification of a novel 1 β-methyl carbapenem antibiotic, S-4661. J Antibiot 1996; 49: 478484.
  • 5
    Iso Y, Irie T, Nishino Y, Motokawa K, Nishitani Y. A novel 1β-methylcarbapenem antibiotic, S-4661. Synthesis and structure–activity relationships of 2-(5-substituted pyrroldin-3-ylthio)-1β-methylcarbapenems. J Antibiot 1996; 49: 199209.
  • 6
    Mori M, Hikida M, Nishihara T, Nasu T, Mitsuhashi S. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J Antimicrob Chemother 1996; 37: 10341036.
  • 7
    Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998; 42: 184187.
  • 8
    Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48: 13841396.
  • 9
    Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 31363140.
  • 10
    Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004; 54: 144154.
  • 11
    Watanabe A, Takahaski H, Kikuchi T et al. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy 2000; 46: 184187.
  • 12
    Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50: 73101.
  • 13
    Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistant selection potential. Antimicrob Agents Chemother 2004; 48: 30863092.
  • 14
    Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004; 48: 13131319.
  • 15
    Andes DR, Kiem S, Craig WA. In vivo pharmacodynamic activity of a new carbapenem, doripenem (DOR), against multiple bacteria in a murine thigh infection model [abstract A308]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2003; 10.
  • 16
    Bhavnani SM, Hammel JP, Cirincioni BB et al. PK-PD target attainment with Monte Carlo simulation (MCS) as decision support of Phase 2/3 dosing strategies for clinical development of doripenem (DOR) [abstract A-11]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2003; 2.
  • 17
    Mikamo H, Izumi K, Hua Y-X, Hayasak Y, Sato Y, Tamaya T. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. J Antimicrob Chemother 2000; 46: 471474.
  • 18
    Nomura S, Nagayama A. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J Chemother 2002; 14: 155160.
  • 19
    National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved standard M7-A6. Wayne, PA: NCCLS, 2003.
  • 20
    National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 14th information supplement. M100-S14. Wayne, PA: NCCLS, 2004.
  • 21
    Arakawa S, Kamidono S Inamatsu T et al. Clinical studies of S-4661, new parenteral carbapenem antibiotic, in complicated urinary tract infections [abstract F218]. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997; 183.
  • 22
    Saito A, Inamatsu T, Shimada J. Clinical studies of S-4661, new parenteral carbapenem antibiotic, in chronic respiratory tract infections [abstract F219]. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997; 183.
  • 23
    Thye DA, Kilfoil T, Leighton A et al. Doripenem: a phase I study to evaluate safety, tolerability and pharmacokinetics in a western healthy volunteer population [abstract A21]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2003; 5.
  • 24
    Kurokawa H, Yagi T, Shibata N, Shibayama K, Arakawa Y. Worldwide proliferation of carbapenem-resistant Gram-negative bacteria. Lancet 1999; 354: 955.
  • 25
    Nordmann P, Poirel L. Emerging carbapanemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321331.
  • 26
    Poirel L, Nordmann P. Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Curr Pharm Biotechnol 2002; 3: 117127.
  • 27
    Nishio H, Komatsu M, Shibata N et al. Metallo-β-lactamase-producing Gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J Clin Microbiol 2004; 42: 52565263.
  • 28
    Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J Antimicrob Chemother 2003; 52: 699702.
  • 29
    Lagatolla C, Tonin EA, Monti-Bragadin C et al. Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-β-lactamase determinants in European hospitals. Emerg Infect Dis 2004; 10: 535538.
  • 30
    Toleman MA, Biedenbach D, Bennett DM, Jones RN, Walsh TR. Italian metallo-β-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. J Antimicrob Chemother 2005; 55: 6170.
  • 31
    Ito H, Arakawa Y, Oshuka S, Wacharotayankun R, Kato N, Ohta M. Plasmid-mediated dissemination of the metallo-β-lactamase gene blaIMP among clinically isolated isolates of Serratia marcescens. Antimicrob Agents Chemother 1995; 39: 824829.
  • 32
    Luzzaro F, Docquier JD, Colinon C et al. Emergence in Klebsiella pneumoniae and Enterobacter cloacae clinical isolates of the VIM-4 metallo-β-lactamase encoded by a conjugative plasmid. Antimicrob Agents Chemother 2004; 48: 648650.
  • 33
    Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR. Emerging epidemic of metallo-β-lactamase-mediated resistances. Diagn Microbiol Infect Dis 2005; 51: 7784.
  • 34
    Livermore DM. Bacterial resistance. Origins, epidemiology, and impact. Clin Infect Dis 2003; 36(suppl 1): S11S23.